Transforming the way we treat chronic lifestyle diseases.
A Little Of Our Story
About Us
Lifestyle diseases, caused by poor diet and physical inactivity among others, are rising worldwide. Each year 70% of all deaths globally – 40 million – are attributed to lifestyle diseases such as obesity, type 2 diabetes and heart disease.
Sigrid is a clinical-stage biotech Company driven by the vision to improve human health through material-based innovations. We are pioneering a new class of engineered materials to prevent and treat lifestyle disease more safely and effectively.
A Breakthrough in Prediabetes Innovation
SiPore15™ is a breakthrough medical device for the safe reduction of blood sugar levels in people at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics. The device is a tasteless and odourless white powder taken with water. Upon its approval, SiPore15™ will be the first treatment available for prediabetes, with the potential to prevent type 2 diabetes.
SiPore15™ is Sigrid Therapeutics’ lead product candidate in clinical development, originating from research at Stockholm University and Karolinska Institute.
A Solution for Prediabetes Underway
Prediabetes Clinical Trials
We are currently planning our new clinical trial SHINE of our lead product candidate SiPore21™, the new and improved Sipore15™, formulated as a consumer-friendly solution for improvement in blood sugar levels in prediabetics and newly diagnosed type 2 diabetics.
Read more on our previous clinical trial STAR by clicking the link below.
”All Disease Begins in the Gut
HippocratesThe Father of Medicine
RESEARCH COLLABORATIONS
